SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, Monga A, Petri E, Rizk DE, Sand PK, Gabriel N, Schaer GN. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn 2010; 29: 420.
  • 2
    Temml C, Haidinger G, Schmidbauer J, Schatzl G, Madersbacher S. Urinary incontinence in both sexes: prevalence rates and impact on quality of life and sexual life. Neurourol Urodyn 2000; 19: 25971.
  • 3
    Milsom I, Abrams P, Cardozo L, Roberts RG, Thüroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001; 87: 7606.
  • 4
    Michel M, Chapple CR. Basic mechanisms of urgency: preclinical and clinical evidence. Eur Urol 2009; 56: 298308.
  • 5
    Mostwin JL. Pathophysiology: the varieties of bladder overactivity. Urology 2002; 5 (Suppl. 1): 227.
  • 6
    Chapple CR. Effects of antimuscarinic treatments in OAB: a systematic review and meta-analysis. Eur Urol 2005; 48: 526.
  • 7
    Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008; 54: 54362.
  • 8
    Caulfield MP, Birdsall NJ. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharrnacol Rev 1998; 50: 27990.
  • 9
    Ancelin ML, Artero S, Portet F, Dupuy A-M, Touchon J, Ritchie K. Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. BMJ 2006; 332: 4558.
  • 10
    Kopelman MD. The cholinergic neurotransmitter system in human memory and dementia: a review. Q J Exp Psychol A 1986; 38: 53573.
  • 11
    Scheife R, Takeda M. Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly. Clin Ther 2005; 27: 14453.
  • 12
    Kay GG, Crook T, Rekeda L, Lima R, Ebinger U, Arguinzoniz M, Steel M. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol 2006; 50: 31726.
  • 13
    Kay GG, Wesnes K. Pharmacodynamic effects of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder, in healthy volunteers. BJU Int 2005; 96: 105562.
  • 14
    Kay GG, Granville L. Antimuscarinic agents: implications and concerns in the management of overactive bladder in the elderly. Clin Ther 2005; 27: 12738.
  • 15
    Kay GG, Abou-Donia MB, Messer JWS, Murphy DG, Tsao JW, Ouslander JG. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J Am Geriatr Soc 2005; 53: 2195201.
  • 16
    Van de Waterbeemd H, Camenisch G, Folkers G, Chretien JR, Raevsky OA. Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. J Drug Target 1998; 6: 15165.
  • 17
    Ertl P, Rohde B, Selzer P. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J Med Chem 2000; 43: 37147.
  • 18
    Eyal S, Hsiao P, Unadkat JD. Drug interactions at the blood-brain barrier: fact or fantasy? Pharmacol Ther 2009; 123: 80104.
  • 19
    Liu X, Che C, Smith BJ. Progress in brain penetration evaluation in drug discovery and development. J Pharmacol Exp Ther 2008; 325: 34956.
  • 20
    Kalvass JC, Maurer TS. Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery. Biopharm Drug Dispos 2002; 23: 32738.
  • 21
    Michel MC. Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. Expert Opin Pharmacother 2008; 9: 178796.
  • 22
    Malhotra BK, Guan Z, Wood N, Gandelman K. Pharmacokinetic profile of fesoterodine. Int J Clin Pharmacol Ther 2008; 46: 55663.
  • 23
    Malhotra BK, Gandelman K, Sachse R, Wood N, Michel MC. The design and development of fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine. Curr Med Chem 2009; 16: 44819.
  • 24
    Feng B, Mills JB, Davidson RE, Mireles RJ, Janiszewski JS, Troutman MD, de Morais SM. In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system. Drug Metab Dispos 2008; 36: 26875.
  • 25
    Kalvass JC, Maurer TS, Pollack GM. Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: comparison of unbound concentration ratios to in vivo P-glycoprotein efflux ratios. Drug Metab Dispos 2007; 35: 6606.
  • 26
    Liu X, Van Natta K, Yeo H, Vilenski O, Weller PE, Worboys PD, Monshouwer M. Unbound drug concentration in brain homogenate and cerebral spinal fluid at steady state as a surrogate for unbound concentration in brain interstitial fluid. Drug Metab Dispos 2009; 37: 7887793.
  • 27
    International Transporter Consortium, Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L. Membrane transporters in drug development. Nat Rev Drug Discov 2010; 9: 21536.
  • 28
    Hitchcock SA, Pennington LD. Structure-brain exposure relationships. J Med Chem 2006; 49: 755983.
  • 29
    Freedman SB, Harley EA, Patel S. Direct measurement of muscarinic agents in the central nervous system of mice using ex vivo binding. Eur J Pharmacol 1989; 174: 25360.
  • 30
    Wesnes K, Warburton DM. Effects of scopolamine and nicotine on human rapid information processing performance. Psychopharmacology 1984; 82: 14750.
  • 31
    Maurer TS, DeBartolo DB, Tess DA, Scott DO. Relationship between exposure and non-specific binding of thirty-three central nervous system drugs in mice. Drug Metab Dispos 2005; 33: 17581.
  • 32
    Hammarlund-Udenaes M, Paalow LK, de Lange CM. Drug equilibration across the blood-brain barrier – pharmacokinetic considerations based on the microdialysis method. Pharm Res 1997; 14: 12834.
  • 33
    Liu X, Smith BJ, Chen C, Callegari E, Becker SL, Chen X, Cianfrogna J, Doran AC, Doran SD, Gibbs JP, Hosea N, Liu J, Nelsom FR, Szewc MA, Van Deusen J. Use of a physiologically based pharmacokinetic model to study the time to reach brain equilibrium: an experimental analysis of the role of blood-brain barrier permeability, plasma protein binding and brain tissue binding. J Pharmacol Exp Ther 2005; 313: 125462.
  • 34
    Rao VV, Dahlheimer LL, Bardgett ME, Snyder AZ, Finch RA, Sartorelli AC, Piwnica-Worms D. Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood–cerebrospinal-fluid drug-permeability barrier. Proc Natl Acad Sci USA 1999; 96: 39005.
  • 35
    Campbell N, Boustani M, Limbil T, Ott C, Fox C, Maidment I, Schubert CC, Munger S, Fick D, Miller D, Gulati R. The cognitive impact of anticholinergics: a clinical review. Clin Interv Aging 2009; 4: 22833.
  • 36
    Oki T, Kageyama YT, Takagi Y, Uchida S, Yamada S. Comparative evaluation of central muscarinic receptor binding activity by oxybutynin, tolterodine and darifenacin used to treat overactive bladder. J Urol 2007; 177: 766770.
  • 37
    Maruyama S, Tsukada H, Nishiyama S, Kakiuchi T, Fukumoto D, Oku N, Yamada S. In vivo quantitative autoradiographic analysis of brain muscarinic receptor occupancy by antimuscarinic agents for overactive bladder treatment. J Pharmacol Exp Ther 2008; 325: 77481.
  • 38
    Kelder J, Wagener M, Timmers M. Cheminformatics and drug design 2004. In: Chemoinformatics Development. History, Review and Current Research, Chapter 5, ed. Noordik JH. Amsterdam: IOS Press, 2004; 11127.
  • 39
    Roberts LM, Black DS, Raman C, Woodford K, Zhou M, Haggerty JE, Yan AT, Cwirla SE, Grindstaff KK. Subcellular localization of transporters along the rat blood-brain barrier and blood-cerebral-spinal fluid barrier by in vitro biotinylation. Neuroscience 2008; 155: 423428.
  • 40
    Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P. Absence of the mdrla P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin. Am J Clin Invest 1995; 96: 1698705.
  • 41
    Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther 2002; 303: 102937.
  • 42
    Chen C, Hanson E, Watson JW, Lee JS. P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists. Drug Met Disp 2003; 31: 3128.
  • 43
    Geyer J, Gavrilova O, Petzinger E. The role of P-glycoprotein in limiting brain penetration of the peripherally acting anticholinergic overactive bladder drug trospium chloride. Drug Metab Dispos 2009; 37: 13714.
  • 44
    Skerjanec A. The clinical pharmacokinetics of darifenacin. Clin Pharmacokinet 2006; 45: 32550.
  • 45
    Michel MC, Minematsu T, Hashimoto T, den Hoven WV, Swart PJ. In vitro studies on the potential of solifenacin for drug–drug-interactions: plasma protein binding and MDR1 transport. Br J Clin Pharmacol 2005; 59: 647.
  • 46
    Mukwaya G, MacGregor T, Hoelscher D, Heming T, Legg D, Kavanaugh K, Johnson P, Sabo JP, McCallister S. Interaction of ritonavir-boosted tipranavir with loperamide does not result in loperamide-associated neurologic side effects in healthy volunteers. Antimicrob Agents Chemother 2005; 49: 490310.
  • 47
    Schinkel AH, Wagenaar E, Mol C, van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996; 97: 251724.
  • 48
    Todorova A, Vonderheid-Guth B, Dimpfel W. Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol 2001; 41: 63644.
  • 49
    Zinner NR, Mattiasson A, Stanton SL. Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. J Am Geriatr Soc 2002; 50: 799807.
  • 50
    Diefenbach K, Arold G, Wollny A, Schwantes U, Haselmann J, Roots I. Effects on sleep of anticholinergics used for overactive bladder treatment in healthy volunteers aged ≥50 years. BJU Int 2005; 95: 3469.
  • 51
    Katz IR, Sands LP, Bilker W, DiFilippo S, Boyce A, D'Angelo K. Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride. J Am Geriatr Soc 1998; 46: 813.
  • 52
    Staskin D, Kay G, Tannenbaum C, Goldman HB, Bhashi G, Ling J, Oefelein MG. Trospium chloride has no effect on memory testing and is assay undetectable in the central nervous system of older patients with overactive bladder. Int J Clin Pract 2010; 64: 1294300.